February 20, 2026
Poland’s regulated market is entering a more enforcement-heavy phase. Two parallel threads matter for operators:
For brands selling into Poland (or fulfilling from elsewhere in the EU), the practical task is to build a defensible product classification and claims posture—and to be ready to pause or reroute SKUs if regulators treat them as unauthorized foods or medicines.
This article is informational only and not legal advice.
Poland’s current trajectory looks less like a single “ban” event and more like a stacking of controls across prescribing, retail claims, and food/consumer safety enforcement.
Trade reporting indicates Poland’s Ministry of Health moved to restrict online prescribing for certain controlled substances, including medical cannabis products, by emphasizing in‑person examination requirements and limiting who can issue an e‑prescription via teleconsultation. Legal commentary on the policy direction (and its likely implementation) highlighted an approach where primary care physicians (POZ) would be the only group able to prescribe certain controlled medicines during an online visit under defined conditions.
The operational result is clear in reported market data: prescription counts peaked around October 2024 and then dropped steeply by the end of 2024, with some reports citing a fall from roughly 68,000 in October 2024 to ~28,000 by December 2024.
External reference points:
Even without a formal nationwide statutory “CBD ban,” food-safety enforcement indicators show increased scrutiny.
The EU’s Rapid Alert System for Food and Feed (RASFF) includes multiple Poland-linked notifications relevant to CBD ingestibles, including:
External references:
Understanding enforcement in Poland requires mapping the authorities by product category.
External reference:
Practical compliance point: in Poland, dietary supplements are typically placed on the market following notification to GIS; however, notification is not the same as “approval,” and authorities can open verification proceedings.
External reference:
External references:
If you sell CBD products into Poland, your highest risk is misclassification—especially where marketing language or form factor signals ingestion.
Across the EU, many CBD extracts intended for ingestion are treated as novel foods under Regulation (EU) 2015/2283 unless a lawful history of significant consumption pre‑15 May 1997 can be demonstrated.
Key practical reality: as of 2026, authorized CBD novel foods remain extremely limited at EU level, and multiple Commission decisions have terminated certain CBD novel food authorization procedures without adding products to the Union list.
External reference:
What this means for your Poland CBD compliance program:
Topical products sit under the EU cosmetics framework, but the moment you imply disease treatment or pharmacological effects, you invite a medicinal classification argument.
Business takeaway:
Poland’s medical system generally channels medical cannabis through pharmacies via prescription, with products often treated as pharmaceutical raw material used for magistral preparations (compounded preparations prepared in a pharmacy).
External reference:
Poland’s domestic hemp framework has moved to a 0.3% THC (and THCA) threshold (dry weight basis) for fibrous hemp definitions following 2022 amendments.
External reference (legal commentary summarizing the amendment):
However, brands should not treat “0.3%” as a universal safe harbor across all product types.
Practical compliance steps:
Poland’s tightening posture is likely to surface first through online scrutiny: product titles, meta descriptions, influencer content, and “before/after” testimonials.
High-risk claim patterns:
Cross-border reality: enforcement can happen even if you ship from another EU country. RASFF entries explicitly reference products “traded online,” highlighting that inspectors and partner authorities watch e-commerce.
Brands often underestimate parcel exposure. If Polish authorities treat a SKU as:
then shipments can face seizure, return, sales bans, and administrative proceedings.
Use this as an internal operating playbook for Poland.
For every SKU sold into Poland, document:
Maintain a single “Poland-ready” dossier containing:
Because the risk is dynamic, prepare in advance:
Even when EU labeling rules apply, Poland expects mandatory information in Polish.
External reference (general food labeling note that compulsory information must appear in Polish; stickers permitted):
Business takeaway:
Even with tighter prescribing, Poland remains a significant medical market, but it is more compliance-sensitive than many newcomers assume.
Poland has historically relied heavily on imports and pharmacy preparation of magistral products. This makes supply continuity sensitive to permits, quotas, and wholesaler/pharmacy readiness.
Marketing of medicinal products is regulated, and Poland has had strict rules around pharmacy advertising (with EU-law scrutiny of the breadth of restrictions). While this is not specific to cannabis, it matters for how brands partner with pharmacies and how they communicate.
External reference (discussion of EU court finding Poland’s pharmacy advertising ban overly restrictive):
Practical compliance steps:
Poland’s compliance story is best tracked by “inflection windows” rather than a single statute date:
Poland’s 2025–2026 environment rewards businesses that can prove compliance quickly: classification logic, testing evidence, labeling controls, and claims governance.
Use https://www.cannabisregulations.ai/ to track regulatory changes, pressure-test product classification, and build a repeatable cannabis compliance program for EU cross-border sales—before a takedown notice, parcel seizure, or administrative fine forces a rushed pivot.
